~~<i id='243CC984CF'><strike id='243CC984CF'><tt id='243CC984CF'><pre id='243CC984CF'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

Wikipedia

leisure time

author：knowledge 2025-09-28 23:49:41 - browse：6742

Adam's take main illustration — Molly Ferguson/STAT

Shares of Apellis Pharmaceuticals are rebounding, driven by a growing belief among some investors that the serious safety issue that has derailed Syfovre, the company’s eye disease treatment, is receding.

Declaring the crisis over is premature, but that could change with more uneventful weeks. Apellis has been a takeout target before, and may be again, at an acquisition price nearly twice its current market value.

Apellis shares rose 32% last week, with most of the gains coming Friday on heavy trading volume. The reason: There have been no new cases of retinal occlusive vasculitis, or ROV, reported in people receiving injections of Syfovre.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： State Dept. review finds Biden bears some blame for Afghanistan failures
Next article： The Readout: Lenmeldy, GLP

focus

entertainment

hotspot

leisure time

explore

focus

WinMcNamee/GettyImagesWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiot

WSS

Scientists successfully use ultrasound imaging to map brain activity

Steward Health Care has deal to sell doctor network to UnitedHealth

Decaf coffee targeted by food safety group under obscure FDA rule

Readout Newsletter: Cardior, Regeneron, Nuvation, Dyne and more

Food as medicine: Medically tailored meals may get standardized

AI used to predict Covid

Wikipedia

leisure time

focus

After affirmative action ruling, medical educators look to 'holistic review'

Merck to buy EyeBio, maker of eye drug, as it grows pipeline

Moonlake's readout produced a cash windfall. Risks remain

Health insurers say they are turning to AI to cut costs, improve care

Anesthesiologist group: stop taking Ozempic before surgery

Abortion pill case raises question: who can sue the FDA?

Novavax promises a turnaround & Lilly roils the obesity market

AI used to predict Covid

After affirmative action ruling, medical educators look to 'holistic review'

Study says nonprofit hospitals fall short in charity care spending

entertainment

Do more moles mean more problems? Not so, says new study

Adam's Biotech Scorecard: Do Sarepta's exon

Covid vaccine financial winners and losers, from Pfizer to Novavax

Merus drug and Keytruda shrank tumors in patients with head and neck cancer

Will generative AI in health care meet the fate of IBM's Dr. Watson?

Oprah kicked off a national conversation on obesity. Let's have it

hotspot

leisure time

explore

focus